Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus MICROZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus MICROZIDE.
HYDRO-RIDE vs MICROZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic